2 news items
Lineage Cell Therapeutics Announces OpRegen Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured At 2024 Retinal Cell & Gene Therapy Innovation Summit
LCTX
6 May 24
in other cohorts) measured at 12 months were sustained at 24 months following a single subretinal administration of OpRegen- Mean change in BCVA
OpRegenĀ® (RG6501) Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit
LCTX
6 May 24
than in other cohorts) measured at 12 months were sustained at 24 months following a single subretinal administration of OpRegen
- Prev
- 1
- Next